Search Results

CureDuchenne, a global nonprofit committed to finding and funding a cure for Duchenne muscular dystrophy, will host webinars in English and Spanish for the Duchenne community after the U.S. Food and Drug Administration approved the expansion to the label indication for ELEVIDYS from Sarepta Therapeutics to include individuals with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene who are at least 4 years of age.

CureDuchenne, a global nonprofit committed to finding and funding a cure for Duchenne muscular dystrophy, announced its FUTURES National Conference will be held from May 23-26 in Orlando

CureDuchenne has announced its schedule of CureDuchenne Cares workshops and dinner sessions for the first half of the year, as well as its annual conference.

CureDuchenne, a leading nonprofit organization dedicated to advancing research and improving the lives of individuals affected by Duchenne muscular dystrophy, is proud to announce the launch of the CureDuchenne Caregiver Course.

Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with rare genetic neuromuscular and neurodegenerative diseases, announced that CureDuchenne Ventures, the strategic investment arm of CureDuchenne, has made an equity investment in Locanabio.

CureDuchenne announced the opening of The CureDuchenne Clinic, providing dedicated care and services to underserved and uninsured individuals with Duchenne and Becker muscular dystrophy.

CureDuchenne Ventures announced funding for MyoGene Bio, LLC, a biotech company developing a novel gene editing therapy for Duchenne muscular dystrophy.

hC Bioscience, a pioneer in the development of tRNA-based therapeutics, received an investment from CureDuchenne Ventures, the strategic investment arm of CureDuchenne, a global nonprofit committed to finding and funding a cure for Duchenne muscular dystrophy.

CureDuchenne announced the promotion of Lianna Orlando, PhD, to Vice President of Research and the addition of Bradley Hodges, PhD as Partner of CureDuchenne Ventures.

CureDuchenne, Muscular Dystrophy Association, and Parent Project Muscular Dystrophy, announced a collaborative clinical trial grant to test repurposing of the FDA-approved drug Vyvgart, for its potential ability to reduce antibodies to adeno-associated virus in Duchenne muscular dystrophy patients.